Product Program year 2025 Source: CMS Open Payments

Frindovyx

Drug Oncology

NDC 83831-120-02

Open in the dashboard

General payments

$6,730

144 payments

Research payments

$0

0 payments

Through program year 2025, $6,730 in general payments and $0 in research payments were reported against Frindovyx (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $6,730 144

Breakdown

Who paid General payments · program year 2025
  1. Avyxa Pharma, LLC $6,730 144 payments
Top recipients General payments · program year 2025
  1. Edward Licitra Medical Oncology · East Brunswick, NJ $400 6% · 2 payments
  2. Samir Desai Hematology & Oncology · Plainfield, IL $270 4% · 1 payment
  3. Salman Waheed Hematology & Oncology · Joliet, IL $270 4% · 1 payment
  4. Ranjana Chauhan Ophthalmology · Hinsdale, IL $270 4% · 1 payment
  5. Shalin Shah Internal Medicine · Plainfield, IL $270 4% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $2,785 42% · 48 practitioners
  2. Medical Oncology Internal Medicine $847 13% · 10 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $528 8% · 19 practitioners
  4. Internal Medicine $411 6% · 6 practitioners
  5. Physician Assistant $391 6% · 10 practitioners

The top 5 of 20 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Illinois $1,223 18% · 7 recipients
  2. New Jersey $724 11% · 6 recipients
  3. Michigan $629 9% · 5 recipients
  4. Nevada $543 8% · 9 recipients
  5. Tennessee $535 8% · 20 recipients

The top 5 of 24 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

144 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record